Delcath (DCTH)
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The...
- Open
- 16.320
- High
- 16.490
- Low
- 16.150
- Prev. Close
- 16.390
- Volume
- 490.94K
- Turnover
- 8.01M
- Avg Price
- 16.314
- Bid/Ask Ratio
- -50.00%
- Amplitude
- 2.07%
- 52wk High
- 17.420
- Volume Ratio
- 1.08
- Turnover Ratio
- 1.71%
Delcath Analyst Rating
View moreForecast & Rating
Aug 7, 2026Price forecast
$24.0046.88%
Forecast & RatingStrong buy
5analysts
- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 14 at 07:10 AM
Delcath Systems adopts Delaware Chancery Court as exclusive forum for internal corporate claims
- Global Report · Aug 13 at 04:43 AM
The Great Consumer Splinter: From Streaming Survival to Wild Crypto Pivots
- Market Beat · Aug 13 at 03:35 AM
Renaissance Technologies LLC Trims Position in Delcath Systems, Inc. $DCTH
- rttnews · Aug 7 at 05:33 AM
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
- Market Beat · Aug 6 at 02:00 PM
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research
- benzinga_article · Aug 6 at 07:47 AM
Delcath Systems shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 sales guidance above estimates.
